Long-term Hydromethylthionine Treatment is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-symptomatic P301S MAPT Mutation Carrier
Manuscript Number:
21-0390R1
Author(s):
Peter Bentham, Charles R. Harrington, Björn O. Schelter, Helen Shiells, Roger T. Staff, Claude M. Wischik
Disclosures
Peter Bentham
Sponsors:
Clinical Advisor - provide advice on study design and interpretation.
Charles R. Harrington
Equity:
I have shares in TauRx Therapeutics Ltd.
Sponsors:
I am employed by TauRx Therapeutics Ltd.
Patents/Royalties
I am a named inventor on patents owned by WisTa Laboratories Ltd., an affiliate of TauRx in the field of Tau protein and inhibitors of protein aggregation.
Grants
Agency:
TauRx Therapeutics Ltd.
Dates:
2002-2021
Björn O. Schelter
Sponsors:
Paid secondment/employment with TauRx Therapeutics Ltd.
Patents/Royalties
Named inventor on patents owned by WisTa Laboratories Ltd. or Genting TauRx Diagnostic Centre, affiliates of TauRx.
Helen Shiells
Sponsors:
Employee at TauRx Therapeutics Ltd.
Patents/Royalties
Named inventor on patents owned by WisTa Laboratories Ltd. or Genting TauRx Diagnostic Centre, affiliates of TauRx.
Roger T. Staff
Consulting Fees:
I have received consulting fees from TauRx
Patents/Royalties
I am a named inventor on patents owned by WisTa Laboratories Ltd
Claude M. Wischik
Equity:
Stock in TauRx Therapeutics
Sponsors:
Contract with TauRx Therapeutics
Patents/Royalties
I am a named inventor on patents owned by WisTa Laboratories Ltd and Genting TauRx Diagnostic Centre relating to tau protein and neurodegenerative disorders.